Ratings by Maxim Group (Naz Rahman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/25/2024 | Alimera Sciences | ALIM | New Coverage | Buy (N/A) |
3.98 (3.54) |
-11.06% | Details | |
| 3/18/2024 | Agile Therapeutics | AGRX | Downgrade | Hold (Buy) |
0.54 (0.60) |
11.11% | Details | |
| 1/31/2024 | Vertex | VRTX | Downgrade | Hold (Buy) |
446.08 (399.92) |
-10.35% | Details | |
| 12/18/2023 | Cingulate | CING | Downgrade | Hold (Buy) |
2.13 (0.89) |
-58.22% | Details | |
| 12/8/2023 | Petros Pharmaceuticals Inc. | PTPI | New Coverage | Buy (N/A) |
1.31 (0.65) |
-50.38% | Details | |
| 11/17/2023 | Palisade Bio Inc. | PALI | Upgrade | Buy (Hold) |
0.52 (4.93) |
848.08% | Details | |
| 11/17/2023 | Processa Pharmaceuticals | PCSA | Downgrade | Hold (Buy) |
0.42 (1.53) |
264.29% | Details | |
| 8/9/2023 | Palisade Bio Inc. | PALI | Downgrade | Hold (Buy) |
1.94 (4.93) |
154.12% | Details | |
| 7/12/2023 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2023 | Vivani Medical, Inc. | VANI | New Coverage | Buy (N/A) |
1.45 (1.67) |
15.17% | Details | |
| 5/19/2023 | Processa Pharmaceuticals | PCSA | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2023 | scPharmaceuticals | SCPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2023 | Palisade Bio Inc. | PALI | Upgrade | Buy (Hold) |
1.68 (4.93) |
193.45% | Details | |
| 1/12/2023 | Processa Pharmaceuticals | PCSA | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2022 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2022 | scPharmaceuticals | SCPH | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2022 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2022 | Clarus | CRXT | Downgrade | Hold (Buy) |
0.21 (0.10) |
-52.38% | Details | |
| 8/19/2022 | Palisade Bio Inc. | PALI | Downgrade | Hold (Buy) |
0.16 (4.93) |
2981.25% | Details | |
| 8/2/2022 | scPharmaceuticals | SCPH | New Coverage | Buy (N/A) |
4.89 (4.57) |
-6.54% | Details | |
| 7/1/2022 | 9 Meter Biopharma | NMTR | Downgrade | Hold (Buy) |
0.26 (0.07) |
-73.08% | Details | |
| 6/21/2022 | 9 Meter Biopharma | NMTR | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2022 | Virpax Pharmaceuticals, Inc. | VRPX | New Coverage | Buy (N/A) |
1.55 (3.30) |
112.9% | Details | |
| 5/9/2022 | 180 Life Sciences Corp. | ATNF | Downgrade | Hold (Buy) |
1.31 (1.80) |
37.4% | Details | |
| 4/19/2022 | Processa Pharmaceuticals | PCSA | New Coverage | Buy (N/A) |
2.87 (1.53) |
-46.69% | Details | |
| 2/25/2022 | NEXGEL | NXGL | New Coverage | Buy (N/A) |
1.81 (2.18) |
20.44% | Details | |
| 1/7/2022 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
1.74 (0.66) |
-62.07% | Details | |
| 1/7/2022 | NeuroSense Therapeutics Ltd. | NRSN | New Coverage | Buy (N/A) |
2.53 (1.35) |
-46.64% | Details | |
| 12/7/2021 | First Wave BioPharma, Inc. | FWBI | Downgrade | Hold (Buy) |
1.40 (2.91) |
107.86% | Details | |
| 10/1/2021 | First Wave BioPharma, Inc. | FWBI | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2021 | Clarus | CRXT | New Coverage | Buy (N/A) |
5.61 (0.10) |
-98.22% | Details | |
| 9/15/2021 | 180 Life Sciences Corp. | ATNF | New Coverage | Buy (N/A) |
5.67 (1.80) |
-68.25% | Details | |
| 8/31/2021 | Palisade Bio Inc. | PALI | New Coverage | Buy (N/A) |
2.73 (4.93) |
80.59% | Details |
